Aaron Logan, MD, PhD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Ave
San Francisco CA 94143
Phone415-502-2110
ORCID ORCID Icon0000-0002-1179-5879 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford UniversityBlood and Marrow Transplantation2012Medicine
    Stanford UniversityHematology2009Medicine
    Stanford UniversityInternal Medicine (Internship and Residency)2008Clinical Investigator Pathway
    University of Southern CaliforniaM.D.2006Keck School of Medicine
    University of Southern CaliforniaPh.D. (Molec Microbio and Immunology)2006Keck School of Medicine
    University of Cambridge, EnglandM.Phil.1997History and Philosophy of Medicine

    Collapse Overview 
    Collapse Overview
    Dr. Aaron Logan is an Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF). His clinical practice focuses on the management of patients with acute leukemias, myelodysplastic syndrome, aplastic anemia and hemophagocytic lymphohistiocytosis. Dr. Logan also runs a research laboratory and is director of the Hematologic Malignancies Tissue Bank at UCSF. Dr. Logan and his laboratory are interested in methods for evaluating clonotypic diversity in the B and T lymphocyte repertoires in patients, particularly following hematopoietic cell transplantation when used to treat blood cancers, bone marrow failure disorders, and congenital immune deficiencies. Methods used in the laboratory currently include T cell receptor excision circle and kappa-deleting recombination circle (TREC/KREC) quantification, high-throughput sequencing of immunoglobulin and T cell receptor genes, and in vitro mixed lymphocyte reactions to identify T cells with specific reactivities. Efforts in the lab are focused on the application of immune repertoire profiling to quantify and track malignancy-, pathogen-, and autoantigen-targeted immune responses following allogeneic transplantation, as well as use of this platform to quantify measurable residual disease in lymphoid malignancies. In Dr. Logan’s lab, the Hematologic Malignancies Tissue Bank at UCSF has been built into a robust resource for samples isolated from patients with a wide diversity of blood cancers and following transplantation. These samples are made available in a deidentified manner to the UCSF and larger research community for cooperative discovery.

    The phone number listed above is Dr. Logan's direct office number.

    If you prefer to contact the outpatient clinic, please call 415-353-2421.

    The clinic fax number is 415-353-2467.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Faculty Mentoring

    Collapse Featured Content 
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. Mol Cancer Ther. 2022 Apr 08; OF1-OF11. Ferng TT, Terada D, Ando M, Tarver TC, Chaudhary F, Lin KC, Logan AC, Smith CC. PMID: 35395091.
      View in: PubMed   Mentions:
    2. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. Am J Hematol. 2022 Jun 01; 97(6):E191-E194. Kennedy VE, Hui G, Azenkot T, Gaut D, Wieduwilt MJ, Oliai C, Jonas BA, Mittal V, Logan AC, Muffly LS, Mannis GN. PMID: 35266185.
      View in: PubMed   Mentions:
    3. SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2022 Mar 05. Logan AC. PMID: 35410757.
      View in: PubMed   Mentions:
    4. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2022 Mar 03. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. PMID: 35247612.
      View in: PubMed   Mentions:
    5. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. Br J Haematol. 2022 04; 197(1):63-70. On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM. PMID: 35174480.
      View in: PubMed   Mentions:
    6. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021 12 02; 138(22):2278-2289. Cutler CS, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta RS, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin JP, Im A, Langston A, Liesveld JL, Juckett M, Logan A, Schachter L, Alavi A, Howard DS, Waksal H, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green LS, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic SZ, Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S. PMID: 34265047; PMCID: PMC8641099.
      View in: PubMed   Mentions: 6     Fields:    
    7. Anthracyclines in a patient with acute leukemia and severe cardiomyopathy requiring mechanical support: A case report. J Oncol Pharm Pract. 2022 Apr; 28(3):729-732. Banerjee R, Lo M, Klein L, Aras M, Logan AC. PMID: 34846217.
      View in: PubMed   Mentions:
    8. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood Cancer Discov. 2021 09; 2(5):434-449. Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C, Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C. PMID: 34514432; PMCID: PMC8425277.
      View in: PubMed   Mentions:
    9. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021 07 08; 138(1):11-22. Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. PMID: 33827116.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    10. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. Eur J Haematol. 2021 Sep; 107(3):343-353. Ngai LL, Ma CY, Maguire O, Do AD, Robert A, Logan AC, Griffiths EA, Nemeth MJ, Green C, Pourmohamad T, van Kuijk BJ, Snel AN, Kwidama ZW, Venniker-Punt B, Cooper J, Manz MG, Gjertsen BT, Smit L, Ossenkoppele GJ, Janssen JJWM, Cloos J, Sumiyoshi T. PMID: 34053123; PMCID: PMC8457079.
      View in: PubMed   Mentions: 3     Fields:    
    11. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021 08 07; 398(10299):491-502. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. PMID: 34097852.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    12. The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond. Curr Hematol Malig Rep. 2021 04; 16(2):132-139. Banerjee R, Kelkar AH, Logan AC, Majhail NS, Pemmaraju N. PMID: 33788125; PMCID: PMC8011363.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. EClinicalMedicine. 2021 Mar; 33:100787. Ljungman P, Bermudez A, Logan AC, Kharfan-Dabaja MA, Chevallier P, Martino R, Wulf G, Selleslag D, Kakihana K, Langston A, Lee DG, Solano C, Okamoto S, Smith LR, Boeckh M, Wingard JR, Cywin B, Fredericks C, Lademacher C, Wang X, Young J, Maertens J. PMID: 33842870; PMCID: PMC8020145.
      View in: PubMed   Mentions: 1  
    14. Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation. J Geriatr Oncol. 2021 05; 12(4):531-539. Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL. PMID: 33059999.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia. Clin Adv Hematol Oncol. 2020 Jul; 18(7):413-422. Akabane H, Logan A. PMID: 32903253.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. Antimicrob Agents Chemother. 2020 03 24; 64(4). Maertens J, Logan AC, Jang J, Long G, Tang JL, Hwang WYK, Koh LP, Chemaly R, Gerbitz A, Winkler J, Yeh SP, Hiemenz J, Christoph S, Lee DG, Wang PN, Holler E, Mielke S, Akard L, Yeo A, Ramachandra S, Smith K, Pertel P, Segal F. PMID: 32015031; PMCID: PMC7179282.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    17. Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2020 01; 26(1):189-196. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL. PMID: 31493541; PMCID: PMC6942208.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    18. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biol Blood Marrow Transplant. 2019 10; 25(10):2002-2007. Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, Flowers MED, Logan AC, Nakamura R, Chang S, Clow F, Lal ID, Styles L, Jaglowski S. PMID: 31260802.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    19. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. Clin Cancer Res. 2019 08 15; 25(16):4917-4923. Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C. PMID: 31152020.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    20. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2019 08; 9(8):1050-1063. McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE. PMID: 31088841.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    21. Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. J Natl Compr Canc Netw. 2019 05 01; 17(5):414-423. Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, Cassaday RD, Litzow M, Advani A, Aoun P, Bhatnagar B, Boyer MW, Bryan T, Burke PW, Coccia PF, Coutre SE, Jain N, Kirby S, Liu A, Massaro S, Mattison RJ, Oluwole O, Papadantonakis N, Park J, Rubnitz JE, Uy GL, Gregory KM, Ogba N, Shah B. PMID: 31085755.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    22. Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood. 2019 05 09; 133(19):2069-2078. Pang WW, Czechowicz A, Logan AC, Bhardwaj R, Poyser J, Park CY, Weissman IL, Shizuru JA. PMID: 30745302; PMCID: PMC6509544.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    23. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 06; 25(6):1218-1224. Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL. PMID: 30708189.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    24. Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. Blood. 2019 05 09; 133(19):2104-2108. Kwon HS, Logan AC, Chhabra A, Pang WW, Czechowicz A, Tate K, Le A, Poyser J, Hollis R, Kelly BV, Kohn DB, Weissman IL, Prohaska SS, Shizuru JA. PMID: 30617195; PMCID: PMC6509543.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    25. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol. 2019 02; 94(2):257-265. Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, Radich J, Kantarjian H. PMID: 30394566; PMCID: PMC6572728.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    26. Plasma Cell-Free DNA Next-Generation Sequencing to Diagnose and Monitor Infections in Allogeneic Hematopoietic Stem Cell Transplant Patients. Open Forum Infect Dis. 2018 Dec; 5(12):ofy301. Fung M, Zompi S, Seng H, Hollemon D, Parham A, Hong DK, Bercovici S, Dolan E, Lien K, Teraoka J, Logan AC, Chin-Hong P. PMID: 30581881; PMCID: PMC6297859.
      View in: PubMed   Mentions: 7  
    27. Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting? Clin Infect Dis. 2018 09 14; 67(7):1142-1143. Fung M, Schwartz BS, Doernberg SB, Langelier C, Lo M, Graff L, Tan M, Logan AC, Chin-Hong P, Babik JM. PMID: 29617983; PMCID: PMC6692592.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    28. Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant. Case Rep Hematol. 2018; 2018:6092646. Rahmat LT, Nguyen A, Abdulhaq H, Prakash S, Logan AC, Mannis GN. PMID: 30225152; PMCID: PMC6129347.
      View in: PubMed   Mentions: 14  
    29. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy. Drugs Today (Barc). 2018 May; 54(5):305-313. Rahmat LT, Logan AC. PMID: 29911695.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    30. Hourigan CS and Logan AC. Measurable Residual Disease for AML, in: Emadi A and Karp JE (Eds). Acute Leukemia: an Illustrated Guide to Diagnosis and Treatment, Demos Medical, New York. 2018.
    31. Logan AC. Sequence-specific MRD for ALL, in: Emadi A and Karp JE (Eds). Acute Leukemia: an Illustrated Guide to Diagnosis and Treatment. Demos Medical, New York. 2018.
    32. Using Social Media at National Meetings in Hematology-Optimal Use, Tips, Strategies, and Limitations. Curr Hematol Malig Rep. 2017 12; 12(6):605-610. Logan AC. PMID: 29076056.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    33. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017 11 23; 130(21):2243-2250. Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S. PMID: 28924018; PMCID: PMC6033048.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    34. Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia. Clin Case Rep. 2017 06; 5(6):891-893. Saba J, Logan AC. PMID: 28588833; PMCID: PMC5457998.
      View in: PubMed   Mentions:
    35. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters. Blood Rev. 2017 05; 31(3):173-183. Chan ST, Logan AC. PMID: 28173959.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    36. What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer. Ann Transl Med. 2016 Dec; 4(24):543. Majure M, Logan AC. PMID: 28149904; PMCID: PMC5233500.
      View in: PubMed   Mentions: 2  
    37. Acute Liver Failure Secondary to Hemophagocytic Lymphohistiocytosis during Pregnancy. ACG Case Rep J. 2016 Aug; 3(4):e162. Giard JM, Decker KA, Lai JC, Gill RM, Logan AC, Fix OK. PMID: 27921061; PMCID: PMC5126497.
      View in: PubMed   Mentions: 3  
    38. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 12 01; 126(12):4640-4653. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. PMID: 27841764; PMCID: PMC5127683.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    39. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016 12 22; 128(25):2899-2908. Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB. PMID: 27802969; PMCID: PMC5179333.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    40. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 11; 22(11):1974-1982. Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. PMID: 27544285; PMCID: PMC5072749.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    41. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 06; 22(6):1030-1036. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. PMID: 26899561.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    42. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 07; 57(7):1560-6. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. PMID: 26490487.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    43. Hematopoietic cell transplantation for chronic lymphocytic leukemia, in: Appelbaum FR, Forman SJ, Negrin RS, Antin JH (Eds). Thomas' Hematopoietic Cell Transplantation, 5th Ed, John Wiley & Sons, Ltd., Chichester, UK. 2015. Logan AC, Miklos DB.
    44. Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease. JAMA Dermatol. 2015 Jun; 151(6):635-7. Sorenson E, McAndrew R, Patel V, Logan AC, Koo J, Levin E. PMID: 25806783.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    45. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. PMID: 25776193.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    46. ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Apr; 21(4):746-54. Logan AC, Wang Z, Alimoghaddam K, Wong RM, Lai T, Negrin RS, Grumet C, Logan BR, Zhang MJ, Spellman SR, Lee SJ, Miklos DB, Center for International Blood and Marrow Transplantation. PMID: 25572032; PMCID: PMC4363312.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    47. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. PMID: 25243620.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    48. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2014 May 27; 111(21):E2219-28. Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M. PMID: 24821775; PMCID: PMC4040579.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    49. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1307-13. Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buño I, Zheng J, Moorhead M, Klinger M, Zhang B, Waqar A, Zehnder JL, Miklos DB. PMID: 24769317; PMCID: PMC5259557.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    50. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013 Aug; 27(8):1659-65. Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, Krampf MR, Jones CD, Waqar AN, Faham M, Zehnder JL, Miklos DB. PMID: 23419792; PMCID: PMC3740398.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    51. Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options. Hematology. 2012 Nov; 17(6):325-8. Dunn T, Cho M, Medeiros B, Logan A, Ungewickell A, Liedtke M. PMID: 23168071.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    52. Cancer vaccines and T cell therapy. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S97-S101. Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J. PMID: 23041602; PMCID: PMC4313548.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    53. Accessory splenules in autoimmune hemolytic anemia. Am J Hematol. 2013 Feb; 88(2):156. Logan A, Berube C, Gotlib J. PMID: 23027373.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. The road to purified hematopoietic stem cell transplants is paved with antibodies. Curr Opin Immunol. 2012 Oct; 24(5):640-8. Logan AC, Weissman IL, Shizuru JA. PMID: 22939368; PMCID: PMC5061494.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    55. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood. 2012 Nov 22; 120(22):4407-17. Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB, Faham M, Dahl G, Lacayo N. PMID: 22932801; PMCID: PMC3507147.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    56. Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Cancer Invest. 2012 Mar; 30(3):231-5. Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA. PMID: 22360362.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    57. Acute lymphoblastic leukemia, in Clinical Decision Support: Hospital Medicine, edited by Wiese J, Auerbach A, Glasheen J, Li J. Decision Support in Medicine, LLC. Wilmington, DE. 2012. Malik UF, Dastaghyab N, Logan AC.
    58. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A. 2011 Dec 27; 108(52):21194-9. Logan AC, Gao H, Wang C, Sahaf B, Jones CD, Marshall EL, Buño I, Armstrong R, Fire AZ, Weinberg KI, Mindrinos M, Zehnder JL, Boyd SD, Xiao W, Davis RW, Miklos DB. PMID: 22160699; PMCID: PMC3248502.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansPHPublic Health
    59. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011 Apr 19; 154(8):529-40. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. PMID: 21502651; PMCID: PMC4102260.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    60. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011 Apr 19; 154(8):516-22. Logan AC, Yank V, Stafford RS. PMID: 21502649; PMCID: PMC4011398.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    61. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 May. Report No.: 10-EHC030-EF. Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care. 2010. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Stave CD, Zehnder JL, Olkin I, McDonald KM, Owens DK, Stafford RS. View Publication.
    62. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology Am Soc Hematol Educ Program. 2010; 2010:153-9. Logan AC, Goodnough LT. PMID: 21239786.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    63. Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. Leuk Lymphoma. 2008 Mar; 49(3):581-5. Kohrt H, Logan A, Temmins C, Witteles R, Liedtke M, Medeiros B. PMID: 18297538.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    64. Factors influencing the titer and infectivity of lentiviral vectors. Hum Gene Ther. 2004 Oct; 15(10):976-88. Logan AC, Nightingale SJ, Haas DL, Cho GJ, Pepper KA, Kohn DB. PMID: 15585113.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    65. Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J Virol. 2004 Aug; 78(16):8421-36. Logan AC, Haas DL, Kafri T, Kohn DB. PMID: 15280451; PMCID: PMC479072.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    66. The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells. J Virol. 2003 Sep; 77(17):9439-50. Haas DL, Lutzko C, Logan AC, Cho GJ, Skelton D, Jin Yu X, Pepper KA, Kohn DB. PMID: 12915559; PMCID: PMC187403.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    67. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr Opin Biotechnol. 2002 Oct; 13(5):429-36. Logan AC, Lutzko C, Kohn DB. PMID: 12459333.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    Aaron's Networks
    Concepts (324)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (58)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-871-g21b54b14 on PROFILES-PWEB01.

    Copyright © The Regents of the University of California